Meeting
2023 ASCO Breakthrough
Effect of ruxolitinib and magrolimab on calreticulin in myelofibrosis CD34+ cells in vitro: Proof of concept for combination therapy.
Authors
Ciro Roberto Rinaldi
University of Lincoln, Lincoln, United Kingdom
Ciro Roberto Rinaldi , Kristian Boasman , Matthew Simmonds
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Breast Cancer,Central Nervous System Tumors,Developmental Therapeutics,Genitourinary Cancer,Hematologic Malignancies,Thoracic Cancers,Other Malignancies or Topics
Sub Track
Immunotherapies
Citation
JCO Global Oncology 9, 2023 (suppl 1; abstr 118)
DOI
10.1200/GO.2023.9.Supplement_1.118
Abstract #
118
Poster Bd #
F1
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Effects of ruxolitinib and magrolimab on calreticulin in myelofibrosis CD34+ cells in vitro: Proof of concept for combination therapy.
First Author: Ciro Roberto Rinaldi
Poster
2024 ASCO Breakthrough
Therapeutically targeting the CALR/CD47 pathway in MPN to reactivate natural immunosurveillance mechanisms within the body to enhance treatment outcomes.
First Author: Ciro Roberto Rinaldi
Poster
2023 ASCO Annual Meeting
Bromodomain and extra-terminal (BET) inhibitor INCB057643 (LIMBER-103) in patients (pts) with relapsed or refractory myelofibrosis (R/R MF) and other advanced myeloid neoplasms: A phase 1 study.
First Author: Justin M. Watts
Poster
2020 ASCO Virtual Scientific Program
Expression of CD47 and CALR in myeloproliferative neoplasms and myelodysplastic syndrome: Potential new therapeutical targets.
First Author: Ciro Roberto Rinaldi